文献速递临床试验与 GCP流行病学与生物统计

硫酸镁预防心脏手术围术期心房颤动:一项随机临床试验——POMPAE试验方案描述

Magnesium sulphate to prevent perioperative atrial fibrillation in cardiac surgery: a randomized clinical trial : A protocol description of the PeriOperative Magnesium Infusion to Prevent Atrial fibrillation Evaluated (POMPAE) trial.
PubMed 文献 · Trials · 2024-08-15

POMPAE试验为2期、单中心、双盲、优效性随机临床研究,计划纳入530例心脏手术患者,按1:1随机分为围术期持续静脉硫酸镁组与安慰剂组,并按是否行瓣膜手术分层。干预目标为维持离子镁在1.5–2.0 mmol/L,主要结局为术后7天内新发术后心房颤动(POAF)发生率,出院时删失。

要点

  • 计划纳入530例心脏手术患者,按1:1随机分组并按是否行瓣膜手术分层。
  • 干预目标为维持离子镁水平在1.5–2.0 mmol/L。
  • 主要结局为术后7天内新发POAF发生率,出院时删失。

核心结论

  • 围术期持续静脉给予硫酸镁可能为预防POAF提供关键证据,并减少心脏手术患者临床不良事件。

研究设计与样本

  • POMPAE试验为2期、单中心、双盲、优效性随机临床研究,计划纳入530例心脏手术患者,按1:1随机分为围术期持续静脉硫酸镁组与安慰剂组,并按是否行瓣膜手术分层。

主要发现

  • 术后心房颤动(POAF)是心脏手术后常见且可能严重的并发症,心脏手术后低镁血症常见,近期证据提示补充镁可能预防POAF。
  • 主要结局指标为术后7天内新发POAF发生率,出院时删失。

关键数值与推荐

  • 干预目标为维持离子镁水平在1.5–2.0 mmol/L。
  • 主要结局为术后7天内新发POAF发生率,出院时删失。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative atrial fibrillation (POAF) is a common and potentially serious complication post cardiac surgery. Hypomagnesaemia is common after cardiac surgery and recent evidence indicates that supplementation of magnesium may prevent POAF. We aim to investigate the effectiveness of continuous intravenous magnesium sulphate administration in the perioperative period to prevent POAF as compared to placebo. METHODS: The (POMPAE) trial is a phase 2, single-center, double-blinded randomized superiority clinical study. It aims to assess the impact of perioperative continuous intravenous magnesium administration on the occurrence of cardiac surgery-related POAF. A total of 530 patients will be included. Eligible patients will be randomized in 1:1 ratio to the intervention or placebo group with stratification based on the presence of valvular surgery. The objective of the infusion is to maintain ionized magnesium levels between 1.5 and 2.0 mmol/L. DISCUSSION: The primary outcome measure is the incidence of de novo POAF within the first 7 days following surgery, with censoring at hospital discharge. This trial may generate crucial evidence for the prevention of POAF and reduce clinical adverse events in patients following cardiac surgery. TRIAL REGISTRATION: The POMPAE trial was registered at ClinicalTrials.gov under the following identifier NTC05669417, https://clinicaltrials.gov/ct2/show/NCT05669417 . Registered on December 30, 2022. PROTOCOL VERSION: Version 3.3, dated 13-01-2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Meerman M, Buijser M, van den Berg L, et al. Magnesium sulphate to prevent perioperative atrial fibrillation in cardiac surgery: a randomized clinical trial : A protocol description of the PeriOperative Magnesium Infusion to Prevent Atrial fibrillation Evaluated (POMPAE) trial. Trials. 2024. PMID: 39148128. doi:10.1186/s13063-024-08368-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。